#USA #Caesarea #IceCure Medical #Cryoablation #ProSense

IceCure Medical Anticipates Record Fourth Quarter Sales in North America

IceCure Medical Ltd., a pioneering company in cryoablation technology, is projecting an impressive rise in its fourth quarter sales in North America, a significant increase from the previous year. This anticipated growth coincides with the FDA's recent marketing authorization of its ProSense® Cryoablation System, specifically designed for treating low-risk breast cancer in women aged 70 and older, which has sparked a surge in demand across the medical community.

After receiving FDA approval in October 2025, IceCure's ProSense® system has garnered significant attention from medical professionals and institutions nationwide. Eyal Shamir, the Chief Executive Officer of IceCure, expressed enthusiasm about the swift interest shown by doctors and patients, noting that numerous factors are driving the upsurge in sales. These include the system's visibility at recent medical conferences, initiatives from breast health organizations, and growing independent study results that underline its efficacy.

IceCure's VP of Sales for North America, Shad Good, highlighted that their sales team is currently engaged with a diverse array of healthcare providers, including hospitals, clinics, and specialists who are increasingly evaluating and ordering the ProSense® system. With a recent order coming from a hospital network recognized among the best globally, this could further heighten demand from a broader spectrum of medical facilities.

The ProSense® Cryoablation System employs unique technology that utilizes liquid nitrogen to freeze tumors, offering a minimally invasive alternative to traditional surgical methods. This innovation not only accelerates recovery but also minimizes complications and pain for patients. Given its convenience and efficacy, the ProSense® system opens up possibilities for outpatient procedures, allowing for quicker treatment timelines in clinical settings.

IceCure plans to publish preliminary revenue results in January 2026, followed by a comprehensive annual report set for April 2026. The extensive media coverage and advocacy for the ProSense® system underscore its potential impact in the healthcare sector, featuring articles in well-known platforms and journals such as Cancer Health, Authority Magazine, and Medscape.

As the healthcare landscape continues to evolve, IceCure Medical stands poised to be at the forefront of innovations in breast cancer treatment, demonstrating the potential of minimally invasive procedures in improving patient outcomes. The company's strategic initiatives, technological advancements, and commitment to addressing patient needs underscore its role in reshaping cancer care.

About IceCure Medical

Founded with the mission to advance non-surgical tumor treatments, IceCure Medical specializes in cryoablation therapy systems. The ProSense® system, the company's flagship product, is regarded as a breakthrough option for treating various tumors, including in the breast, kidney, lung, and liver. Through its dedication to innovation, IceCure aims to provide effective, safe, and convenient treatment options that align with contemporary patient care standards.

With the ongoing support from healthcare professionals and institutions, IceCure is on track to redefine the standards of care for patients facing surgery, offering them hope and accessible solutions for treatment within their communities.